Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Functional Magnetic Resonance Imaging (fMRI) Investigation of Nicotine Withdrawal Symptoms
This study has been terminated.
Sponsored by: GlaxoSmithKline
Information provided by: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00657020
  Purpose

A single centre, evaluator and subject blind, randomised, placebo controlled, two-administration, two-period crossover study conducted in adult smokers. Subjects wil attend a screening visit and two treatment visits. Treatment visits will be separated by at least 48 hours (hrs).


Condition Intervention Phase
Healthy Volunteer Smokers
Drug: Nicotine
Phase IV

MedlinePlus related topics: MRI Scans
Drug Information available for: Nicotine polacrilex Nicotine tartrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Single Blind, Placebo Control, Crossover Assignment, Pharmacodynamics Study
Official Title: Simultaneous fMRI/EEG of the 4 mg Nicotine Lozenge in Relief of Cognitive Impairment Associated With Nicotine Withdrawal

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • To compare the effect of nicotine replacement therapy to placebo on blood oxygen level dependent activation associated with attention in abstinent smokers

Secondary Outcome Measures:
  • To compare the effect of nicotine replacement therapy to placebo on cognitive measures of attention in abstinent smokers

Estimated Enrollment: 30
Study Start Date: September 2007
Study Completion Date: February 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Age Aged between 18 and 55 years inclusive.
  • Weight and size

    1. Body mass index (BMI) within the range 19.0-32.0 kg/m.
    2. Able to fit comfortably within the MR scanner.
  • Smoking Status

    1. Cigarette smokers that consume their first manufactured cigarette (i.e., not self rolled cigarettes) within 30 min of waking.
    2. Individuals who have smoked regularly for at least a year.
  • General Status

    1. Right handed subjects.
    2. Able to read and write (in English) at a level sufficient to complete study related assessments.
  • Contraception Females of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.
  • Compliance Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • General Health Good general health with (in the opinion of the examining study doctor) no clinically significant and relevant abnormalities of medical history, physical examination or clinical laboratory test.
  • Consent Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written informed consent and has received a signed and dated copy of the informed consent form.

Exclusion Criteria:

  • Pregnancy Women who are pregnant or who have a positive urine pregnancy test.
  • Breast-feeding Women who are breast-feeding.
  • Disease/Illness

    1. Any clinically significant medical history or abnormality found on physical examination, laboratory assessment or electrocardiogram (ECG) at screening which, in the opinion of the investigator, could interfere with the interpretation of efficacy or safety data or which otherwise would contraindicate participation in a clinical trial.
    2. Current or recent history or presence of a neurological diagnosis (not limited to but including for example, stroke, traumatic brain injury, carotid arterial sclerotic disease, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, vascular dementia, transient ischemic attack, schizophrenia, major depression etc.) that may influence the outcome or analysis of the scan results.
  • Contraindications to MR scanning

    1. Intracranial aneurysm clips (except Sugita).
    2. History of intra-orbital metal fragments that have not been removed by a doctor (as confirmed by orbital X-Ray).
    3. Inner ear implants.
    4. Tattoos with metal containing inks or piercings that can not be removed except those, which, in the opinion of the Investigator, will not interfere with the study procedures or compromise safety.
    5. History of claustrophobia or subject feels unable to lie still on their back for a period of 90 min in the MR scanner.
    6. Presence of a cardiac pacemaker or other electronic device or ferromagnetic metal foreign bodies in vulnerable positions as assessed by a standard pre-MRI questionnaire supported by plain X-Rays where appropriate.
  • Prior/Concomitant Medication

    1. Use of any central nervous system (CNS) active, prescription medication within 14 days of first treatment visit.
    2. Use of any over the counter (OTC) medication within 14 days of each treatment visit except those, which, in the opinion of the Investigator, will not interfere with the study procedures or compromise safety. Paracetamol (up to 2 g) may be taken up to 24 hrs prior to each treatment visit.
    3. Current use of any nicotine replacement therapy.
  • Clinical Study/Experimental Medication

    1. Participation in another clinical study or receipt of an investigational drug within 3 months of the first treatment visit.
    2. Previous participation in this study.
  • Allergy/Intolerance Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
  • Substance abuse

    1. History of regular alcohol consumption exceeding an average weekly intake of more than 14 units per week for females, 21 units per week for males, or an average daily intake greater than 2 units for females and 3 units for males.
    2. Past history of drug abuse (i.e. meeting DSM IV [American Psychiatric Association, 1994] or ICD 10 [World Health Organization, 1990] criteria for substance dependence), excluding nicotine, or has tested positive for urine drugs of abuse at the screening or either treatment visit.
  • Alcohol Consumption of any alcoholic beverages within 24 hours of the treatment visits (as indicated by either a positive breath alcohol test or in the opinion of the Investigator).
  • Caffeine Consumption of large quantities of xanthine containing beverages (e.g., coffee, tea, cola, chocolate etc, more than an average of five cups or glasses per day).
  • Personnel An employee of the sponsor or the study site or members of their immediate family.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00657020

Locations
United Kingdom
GSK Investigational Site
London, United Kingdom, W6 8RF
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials, MD GlaxoSmithKline
  More Information

Study ID Numbers: S3250493
Study First Received: April 2, 2008
Last Updated: April 11, 2008
ClinicalTrials.gov Identifier: NCT00657020  
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
nicotine
replacement
therapy
fMRI/EEG

Study placed in the following topic categories:
Nicotine polacrilex
Nicotine
Healthy

Additional relevant MeSH terms:
Neurotransmitter Agents
Cholinergic Agonists
Molecular Mechanisms of Pharmacological Action
Nicotinic Agonists
Physiological Effects of Drugs
Central Nervous System Stimulants
Cholinergic Agents
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Ganglionic Stimulants
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on January 16, 2009